Ondansetron

Club foot / Talipes equinovarus

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S2853
R3977		 Parker, BDS study, 2018 Club foot 1st trimester case control unexposed, sick Adjustment: Yes 0.90 [0.60;1.30] 29/404   375/5,873 404 404
ref
S2778
R3786		 Fejzo (Mainly exposed to other treatements, sick), 2016 Club foot 1st trimester retrospective cohort exposed to other treatment, sick excluded Adjustment: No 0.15 [0.01;3.79] C
excluded (control group) 		0/952   1/441 1 952
ref
S2776
R3748		 Fejzo (Unexposed control, disease free), 2016 Club foot 1st trimester retrospective cohort unexposed, disease free Adjustment: No 1.35 [0.03;68.15] C 0/952   0/1,286 0 952
ref
S2859
R59303		 Werler, 2014 Isolated Clubfoot without first-degree history 1st trimester case control unexposed (general population or NOS) Adjustment: Yes 1.47 [0.95;2.27] 32/121   538/2,471 570 121
ref
S2746
R3907		 Pasternak, 2013 Club foot 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: No 1.50 [0.40;5.67] C 3/1,233   8/4,932 11 1,233
ref
Total 4 studies 1.13 [0.85;1.50] 985 2,710
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Parker, BDS study, 2018Parker, BDS study, 2018 0.90[0.60; 1.30]40440453%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Fejzo (Unexposed control, disease free), 2016Fejzo, 2016 1 1.35[0.03; 68.15]09521%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Werler, 2014Werler, 2014 1.47[0.95; 2.27]57012142%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: moderateROB mesure: moderateROB reporting: moderate Pasternak, 2013Pasternak, 2013 1.50[0.40; 5.67]111,2334%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (4 studies) I2 = 0% 1.13[0.85; 1.50]9852,7100.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Unexposed control, disease free;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.49[0.42; 5.23]112,1850%criticalFejzo (Unexposed control, disease free), 2016 Pasternak, 2013 2 case control studiescase control studies 1.14[0.70; 1.84]97452563%criticalParker, BDS study, 2018 Werler, 2014 2 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.47[0.98; 2.22]5812,3060%criticalFejzo (Unexposed control, disease free), 2016 Werler, 2014 Pasternak, 2013 3 unexposed, sickunexposed, sick 0.90[0.61; 1.32]404404 -criticalParker, BDS study, 2018 1 Tags Adjustment   - No  - No 1.49[0.42; 5.23]112,1850%criticalFejzo (Unexposed control, disease free), 2016 Pasternak, 2013 2   - Yes  - Yes 1.14[0.70; 1.84]97452563%criticalParker, BDS study, 2018 Werler, 2014 2 All studiesAll studies 1.13[0.85; 1.50]9852,7100%criticalParker, BDS study, 2018 Fejzo (Unexposed control, disease free), 2016 Werler, 2014 Pasternak, 2013 40.25.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-4.74.82.4010.000Parker, BDS study, 2018Fejzo (Unexposed control, disease free), 2016Werler, 2014Pasternak, 2013

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 2778

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.47[0.98; 2.22]5812,3060%NAFejzo (Unexposed control, disease free), 2016 Werler, 2014 Pasternak, 2013 3 unexposed, sick controlsunexposed, sick controls 0.90[0.61; 1.32]404404 -NAParker, BDS study, 2018 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls Out of scale0.15[0.01; 3.79]1952 -NAFejzo (Mainly exposed to other treatements, sick), 2016 10.510.01.0